{"disease":{"id":"b-cell-malignancies","name":"b cell malignancies"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07283965","title":"Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT06561243","title":"Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT02473757","title":"Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04277637","title":"Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":437,"lead_sponsor_name":"BeOne Medicines","has_results":false},{"nct_id":"NCT02343120","title":"Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":385,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT02327078","title":"A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06576102","title":"Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":204,"lead_sponsor_name":"Maddalena Giannella","has_results":false},{"nct_id":"NCT02457598","title":"Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":203,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03050190","title":"A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT01010217","title":"Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06542250","title":"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07515313","title":"Expression of CD274 (PD-L1) and CD276 in B-cell Malignancies: A Study by Flowcytometry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":159,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT00983619","title":"A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT05724121","title":"Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax","phase":"","overall_status":"RECRUITING","enrollment_count":135,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT06958679","title":"Evaluation of SYS6005 in Patients With Advanced Malignant Tumor","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"CSPC Megalith Biopharmaceutical Co.,Ltd.","has_results":false},{"nct_id":"NCT02825836","title":"Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"Telios Pharma, Inc.","has_results":false},{"nct_id":"NCT01905813","title":"Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":121,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT02569476","title":"BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT04509700","title":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03932331","title":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":105,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03125577","title":"Combination CAR-T Cell Therapy Targeting Hematological Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT04430530","title":"4SCAR-T Therapy Post CD19-targeted Immunotherapy","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT02018861","title":"A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT05665530","title":"A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT07493174","title":"Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":86,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT04014205","title":"A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":81,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT04865458","title":"A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Sunshine Lake Pharma Co., Ltd.","has_results":false},{"nct_id":"NCT06316427","title":"Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT06351527","title":"Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"InnoCare Pharma Inc.","has_results":false},{"nct_id":"NCT05780034","title":"A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Accutar Biotechnology Inc","has_results":false},{"nct_id":"NCT05432882","title":"CD19/22 Bi-specific CAR-T Cell Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT05436509","title":"CD19/79b Bi-specific CAR-T Cell Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT04689308","title":"This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":57,"lead_sponsor_name":"Minghui Pharmaceutical (Shanghai) LTD","has_results":false},{"nct_id":"NCT04172246","title":"Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT07070323","title":"A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT06316856","title":"CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT07135466","title":"A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Sheba Medical Center","has_results":false},{"nct_id":"NCT07349849","title":"Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":47,"lead_sponsor_name":"Xinqiao Hospital of Chongqing","has_results":false},{"nct_id":"NCT05683717","title":"A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"TransThera Sciences (Nanjing), Inc.","has_results":false},{"nct_id":"NCT03198650","title":"A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01957579","title":"A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT05436496","title":"CD19/70 Bi-specific CAR-T Cell Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT07002112","title":"The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05995015","title":"4SCAR19U T Cells Targeting B Cell Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT02457559","title":"Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05336409","title":"A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":28,"lead_sponsor_name":"Century Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07345728","title":"Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies","phase":"NA","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Donghua Zhang","has_results":false},{"nct_id":"NCT04551963","title":"Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT03642496","title":"Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}